SCHEMBL837890

SCHEMBL837890

N[C@H](Cc1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.65
PTGS1 P23219 2/20 0.65
ALPI P09923 1/20 0.65
PKM P14618 1/20 0.65
XIAP P98170 1/20 0.65
HTR2A P28223 2/20 0.60
PTPN1 P18031 1/20 0.60
KDM4E B2RXH2 1/20 0.60
USP2 O75604 1/20 0.60
EGFR P00533 1/20 0.60
LCK P06239 1/20 0.60
FYN P06241 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
ALOX15 P16050 1/20 0.60
PTGS2 P35354 1/20 0.60
RECQL P46063 1/20 0.60
HIF1A Q16665 1/20 0.60
HSD17B10 Q99714 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HTR2C P28335 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210104 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29554654 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29401985 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93304 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29375097 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL29584308 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93303 1.00 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL5967402 0.98 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL2344880 0.98 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL29398635 0.98 SLC7A5 (0.62) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122074077-A Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte stimulating hormone analogs for imaging or therapy 省卫生服务机构 2026-05-22 CN claimed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 US claimed
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 US claimed
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF ALPHA 9 ONCOLOGY INC (CA) 2026-03-19 US claimed
EP-4711004-A2 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2026-03-18 EP claimed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 US claimed
US-12459973-B2 Peptide compounds for reducing side effects of CB1 receptor agonists UNIVERSITAT DE BARCELONA (ES) 2025-11-04 US claimed
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2025-06-19 US claimed
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-06-19 US claimed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 CN claimed
CN-114641486-A For reducing CB1Peptide compounds of side effects of receptor agonists 庞培法布拉大学 2022-06-17 CN claimed
US-20220162261-A1 NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. 2022-05-26 US claimed
EP-3997105-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Protagonist Therapeutics, Inc. (US) 2022-05-18 EP claimed
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2022-04-28 US claimed
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2022-04-28 US claimed
CN-114341161-A Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases 领导医疗有限公司 2022-04-12 CN claimed
WO-2022067086-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. (US) 2022-03-31 WO claimed
CN-109196004-B Engineered scaffold for vascularized tissue repair 加利福尼亚大学董事会 2022-03-18 CN claimed
WO-2022054062-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS BAR ILAN UNIVERSITY (IL) 2022-03-17 WO claimed
US-20220040340-A1 RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2022-02-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616760-B2 Synthetic cyclic peptide mimetics TPX2, IAPP, HAX1 SLC7A5 326/4885PTGS1 4267/4885ALPI 3217/4885
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST MC4R, NPY4R, MC3R SLC7A5 2049/4885PTGS1 3113/4885ALPI 1852/4885
US-12459973-B2 Peptide compounds for reducing side effects of CB1 receptor agonists CNR2, CNR1, OPRD1 SLC7A5 869/4885PTGS1 1482/4885ALPI 2697/4885
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS THRB, MC1R, MC5R SLC7A5 333/4885PTGS1 1376/4885ALPI 3090/4885
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A SLC7A5 4092/4885PTGS1 88/4885ALPI 1924/4885
US-20220040340-A1 RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY MC1R, MC3R, MC5R SLC7A5 219/4885PTGS1 3353/4885ALPI 2556/4885
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS MC4R, MC5R, MC3R SLC7A5 4056/4885PTGS1 4265/4885ALPI 4091/4885
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R SLC7A5 1414/4885PTGS1 2040/4885ALPI 2493/4885
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS MC3R, MC1R, MC5R SLC7A5 998/4885PTGS1 2605/4885ALPI 3902/4885
US-20260077073-A1 GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF GRPR, GIPR, GLP1R SLC7A5 670/4885PTGS1 1358/4885ALPI 1415/4885
US-20220162261-A1 NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS EPCAM, VCAM1, ITGB7 SLC7A5 506/4885PTGS1 3965/4885ALPI 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.